RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. (RVMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Value (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | D+ (1.8) | A+ (4.5) | C- (2.0) | B- (3.1) | C+ (2.6) | C+ (2.8) |
| 2026-11-07 | C+ (2.5) | B (3.3) | D+ (1.8) | B- (3.1) | C+ (2.7) | C+ (2.7) |
| 2026-10-31 | C+ (2.5) | B (3.2) | D+ (1.8) | B (3.3) | C+ (2.7) | C+ (2.7) |
| 2026-10-24 | C+ (2.5) | B- (3.1) | D+ (1.8) | B- (3.1) | C+ (2.6) | C+ (2.6) |
| 2026-10-17 | C+ (2.5) | B- (3.1) | D+ (1.8) | B- (3.0) | C+ (2.6) | C+ (2.6) |